研究者情報

ユウドウ　カズオ   YUDO KAZUO   遊道和雄    所属   大学院医学研究科 難治性疾患病態制御学    職種   大学院教授
論文種別	総説・解説
言語種別	英語
査読の有無	査読あり
表題	Chemokines and chemokine receptors as promising targets in rheumatoid arthritis
掲載誌名	正式名：Front Immunol ISSNコード：16643224
掲載区分	国外
巻・号・頁	14,1100869頁
著者・共著者	Murayama M.A, Shimizu J, Miyabe C, Yudo K, Miyabe Y.
発行年月	2023/02
概要	Rheumatoid arthritis (RA) is an autoimmune disease that commonly causes inflammation and bone destruction in multiple joints. Inflammatory cytokines, such as IL-6 and TNF-α, play important roles in RA development and pathogenesis. Biological therapies targeting these cytokines have revolutionized RA therapy. However, approximately 50% of the patients are non-responders to these therapies. Therefore, there is an ongoing need to identify new therapeutic targets and therapies for patients with RA. In this review, we focus on the pathogenic roles of chemokines and their G-protein-coupled receptors (GPCRs) in RA. Inflamed tissues in RA, such as the synovium, highly express various chemokines to promote leukocyte migration, tightly controlled by chemokine ligand-receptor interactions. Because the inhibition of these signaling pathways results in inflammatory response regulation, chemokines and their receptors could be promising targets for RA therapy. The blockade of various chemokines and/or their receptors has yielded prospective results in preclinical trials using animal models of inflammatory arthritis. However, some of these strategies have failed in clinical trials. Nonetheless, some blockades showed promising results in early-phase clinical trials, suggesting that chemokine ligand-receptor interactions remain a promising therapeutic target for RA and other autoimmune diseases.
DOI	10.3389/fimmu.2023.1100869
文献番号	36860872